Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2016-004539-18-FR
EUCTR2016-004539-18-FRActive, not recruitingPhase 1

A Phase 2, Open-Label, Multicenter, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF–Rho™ in Patients with Chronic Neutropenia

Prolong Pharmaceuticals, LLC0 sites10 target enrollmentStarted: July 3, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
10
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1) Patients 12 years of age or older
  • •2) Patients with established Chronic, cyclic or idiopathic severe neutropenia defined as Median ANC < 0.5 x 109/L at diagnosis (both with and without demonstrated genetic lesion) having an indication for treatment by GCSF. Patients on GCSF & PEG-GCSF treatment are still eligible to participate after a washout period of 7 days (after GCSF) or 14 days after PEG-GSCF, after the stopping of the drug
  • •3) Signed and dated informed written consent/assent by the patient/parent
  • •4) Women of childbearing potential with a negative serum pregnancy test and using a reliable method of contraception during the study period. Male study participants also agreeing to use contraception for the study period
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 3
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 6
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 1

Exclusion Criteria

  • •A subject will not be enrolled if they meet any of the following criteria:
  • •1) Evidence of chromosomal abnormalities, myelodysplasia, hematologic malignancy, aplastic anemia, systemic lupus erythematosus, or rheumatoid arthritis (Felty’s syndrome) or if the neutropenia was drug-induced
  • •2) Progressive malignant disease or malignancy history
  • •3) Presence of macrophage activation syndrome before the diagnosis of neutropenia
  • •4) Presence of a permanent proteinuria before the diagnosis of neutropenia
  • •5) Clinical Significant Abnormal Renal, Cardiac, Hepatic Function or Blood Coagulation
  • •6) Patient has a chronic infection such as hepatitis B virus(HBV), hepatitis C Virus (HCV) or Human immunodeficiency virus( HIV) or history of tuberculosis
  • •7) Association with anemia <8 g/dL or thrombocytopenia (except iron deficiency anemia inflammatory except Shwachman syndrome) before the diagnosis of neutropenia
  • •8) Drug abuse, substance abuse, or alcohol abuse
  • •9) Use of any other investigational drug at the time of enrollment, or within 5 half-lives prior to enrollment, whichever is longer
  • •10) Patients unwilling and/or who are not capable of ensuring compliance with the provisions of the study protocol
  • •11) Pregnant or breastfeeding women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test
  • •12) Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are using a highly effective method of birth control (i.e., one that results in a less than 1% per year failure rate when used consistently and correctly, such as implants, injectables, combined oral contraceptives and intrauterine devices (IUDs)). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) is not acceptable
  • •13) For patients with glycogen storage disease and G6PC3 neutropenia, Pulmonary hypertension should be determined by ECHO and if positive patient is not eligible for the study

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Phase II/Ill, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine inPreterm Subjects Ages 28 Weeks to < 36 Weeks Gestational Age
EUCTR2017-000408-71-Outside-EU/EEAHospira Inc6
Active, not recruiting
Phase 1
An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone
EUCTR2006-006964-48-FRAmgen Inc34
Active, not recruiting
Phase 1
Isatuximab in Combination with REGN2810 (cemiplimab) in Patients with Advanced Maligancies- Prostate cancer- Non-small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-002846-61-ITSanofi-aventis recherche & développement168
Active, not recruiting
Phase 1
Isatuximab in Combination with REGN2810 (cemiplimab) in Patients with Advanced Maligancies- Prostate cancer - Non-small cell lung cancerMedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-002846-61-GBSanofi-aventis recherche & développement168
Active, not recruiting
Phase 1
A Study of Isatuximab-based Therapy in Participants with Lymphoma
EUCTR2018-002442-37-NLSanofi-aventis recherche & developpement145